Yan Kexin, Wang Yutao, Shao Yining, Xiao Ting
Department of Dermatology, The First Hospital of China Medical University, National Health Commission Key Laboratory of Immunodermatology, Key Laboratory of Immunodermatology of Ministry of Education, Shenyang, Liaoning, China.
Department of Urology, China Medical University, The First Hospital of China Medical University, Shenyang, Liaoning, China.
J Oncol. 2021 May 25;2021:5582920. doi: 10.1155/2021/5582920. eCollection 2021.
Melanoma is a common tumor characterized by a high mortality rate in its late stage. After metastasis, current treatment methods are relatively ineffective. Many studies have shown that long noncoding RNA (lncRNA) may participate in gene mutation and genomic instability in cancer.
We downloaded transcriptome data, mutation data, and clinical follow-up data of melanoma patients from The Cancer Genome Atlas. We divided samples into groups according to the number of somatic cell mutations and then performed a differential analysis to screen out the differentially expressed genes. We then divided samples into genomic unstable and genomic stable groups. We compared lncRNA expression profiles in these groups and constructed a protein-coding genes network coexpressed with selected lncRNA to analyze the pathways enriched by these genes. Two machine learning methods, least absolute shrinkage and selector operation (LASSO) and support vector machine-recursive feature elimination (SVM-RFE), were applied to conduct the lncRNA-related prognostic model. Afterward, we performed survival analysis, risk correlation analysis, independent prognostic analysis, and clinical subgroup model validation. Finally, through wound healing assay and transwell assay, the function of AATBC was verified by A375 cell lines.
We screened 61 prognostic-related lncRNAs and constructed an lncRNA-mRNA coexpression network based on these lncRNAs. Seven lncRNAs were selected as common characteristic factors based on the two machine learning methods. The model formula was as follows: risk score = 0.085AATBC + 0.190 AC026689.1-0.117AC083799.1 + 0.036 AC091544.6-0.039 LINC01287-0.291 SPRY4.AS1 + 0.056 ZNF667.AS1. The seven lncRNAs in this formula are key candidates. Cell experiments have verified that knocking down AATBC in A375 cell lines can reduce the proliferation and invasion ability of melanoma cells.
The lncRNA we identified provides a new way to study lncRNA's role in the genomic instability of melanoma. Our findings may provide essential candidate biomarkers for the diagnosis and treatment of melanoma.
黑色素瘤是一种常见肿瘤,其晚期死亡率很高。转移后,目前的治疗方法相对无效。许多研究表明,长链非编码RNA(lncRNA)可能参与癌症中的基因突变和基因组不稳定。
我们从癌症基因组图谱下载了黑色素瘤患者的转录组数据、突变数据和临床随访数据。我们根据体细胞突变数量将样本分组,然后进行差异分析以筛选出差异表达基因。然后我们将样本分为基因组不稳定组和基因组稳定组。我们比较了这些组中的lncRNA表达谱,并构建了与选定lncRNA共表达的蛋白质编码基因网络,以分析这些基因富集的途径。应用两种机器学习方法,即最小绝对收缩和选择算子(LASSO)以及支持向量机递归特征消除(SVM-RFE)来构建lncRNA相关的预后模型。随后,我们进行了生存分析、风险相关性分析、独立预后分析和临床亚组模型验证。最后,通过伤口愈合试验和Transwell试验,利用A375细胞系验证了AATBC的功能。
我们筛选出61个与预后相关的lncRNA,并基于这些lncRNA构建了lncRNA-mRNA共表达网络。基于这两种机器学习方法,选择了7个lncRNA作为共同特征因子。模型公式如下:风险评分=0.085AATBC + 0.190 AC026689.1 - 0.117AC083799.1 + 0.036 AC091544.6 - 0.039 LINC01287 - 0.291 SPRY4.AS1 + 0.056 ZNF667.AS1。该公式中的7个lncRNA是关键候选者。细胞实验已证实,在A375细胞系中敲低AATBC可降低黑色素瘤细胞的增殖和侵袭能力。
我们鉴定出的lncRNA为研究lncRNA在黑色素瘤基因组不稳定中的作用提供了新途径。我们的发现可能为黑色素瘤的诊断和治疗提供重要的候选生物标志物。